Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD1 | P21728 | 5/20 | 0.49 |
| ▸ | DRD5 | P21918 | 5/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL20854709 | 0.98 | DRD2 (0.48) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL20869491 | 0.85 | DRD2 (0.54) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL470075 | 0.78 | DRD2 (0.65) | DRD2DRD1DRD5DRD3DRD4 | |
| Bromide SCHEMBL11819645 | 0.77 | DRD2 (0.55) | DRD2DRD1DRD5DRD3DRD4 | |
| Bromide SCHEMBL11817641 | 0.75 | DRD1 (0.58) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL17607348 | 0.74 | RAC1 (0.38) | MAPT | |
| SCHEMBL17462481 | 0.72 | DRD2 (0.51) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL7271975 | 0.71 | EGFR (0.42) | DRD2DRD1MAPT | |
| SCHEMBL6783570 | 0.70 | MAOA (0.47) | DRD2DRD1DRD5DRD3DRD4 | |
| SCHEMBL17815299 | 0.70 | MAOA (0.49) | DRD2DRD1DRD5DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019070973-A1 | CEPHEM COMPOUNDS WITH LATENT REACTIVE GROUPS | GLADIUS PHARMACEUTICALS CORPORATION (CA) | 2019-04-11 | — | — | WO | disclosed |
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | GLADIUS PHARMACEUTICALS INC (CA) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100534-A1 | Cephem Compounds with Latent Reactive Groups | PGLS, GNE, COMT | DRD2 1186/4885DRD1 2003/4885DRD5 4048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.